3.7☒.1 days, respectively, without parenteral anticoagulants (p<0.001). 3.9☓.7 days for warfarin with parenteral anticoagulants (p<0.001), and 2.7☑.7 days vs. Specifically, the number of hospital days for XARELTO® was 2.4☑.7 days vs. Findings showed the number of hospital days from first dose to discharge was lower for the XARELTO® group, when initiated with or without parenteral anticoagulants, compared to the warfarin group. These anticoagulants were administered intravenously or via infusion to approximately 64 percent of patients in each group. In the study, researchers also examined how the use of parenteral anticoagulants, including low-molecular-weight heparin (LMWH) or unfractionated heparin, impacted LOS. Shorter LOS also was observed for XARELTO® across stratified comparator groups, specifically provoked VTE (i.e., when VTE occurs with an identifiable cause) and unprovoked VTE (i.e., when VTE occurs in the absence of an identifiable cause) compared to the warfarin group. For LOS, people taking XARELTO® stayed at the hospital an average of 1.57 fewer days (3.7☓.1 days vs.For hospitalization costs, the XARELTO® group had an average savings of $1,888 per admission ($8,387 vs.Researchers found total hospitalization costs were significantly lower and LOS was significantly shorter for people taking XARELTO® compared to those receiving warfarin: Total hospitalization costs (which included room rate, laboratory tests, inpatient procedures, pharmacy costs and all other inpatient services) were evaluated the analysis also looked at length of stay (LOS). Each group included 1,223 patients (751 PE patients and 472 DVT patients), with an average age of 64 years. Patients were identified from the Truven MarketScan Hospital Drug Database between November 2012 and December 2013. The study evaluated 2,446 people who were admitted to the hospital following a primary VTE diagnosis and were treated with either XARELTO® or warfarin. While not a substitute for clinical trials, this analysis complements EINSTEIN, the Phase 3 clinical program used by regulatory authorities worldwide to approve rivaroxaban for the treatment of DVT and PE and long-term protection against the risk of VTE recurrence, and provides important insights for healthcare systems looking for ways to reduce the cost burden of managing these conditions," he continued. "This study found use of rivaroxaban was associated with lower total hospitalization costs, shorter hospital stays and a simplified treatment regimen compared to warfarin. "Venous thromboembolism, or VTE, represents a tremendous burden to our healthcare system, as the cost of treating these blood clots remains so high," said Steven Deitelzweig, MD, System Chairman of Hospital Medicine, Medical Director of Regional Business Development, Ochsner Clinic Foundation, New Orleans, LA. healthcare system between $13.5 and $27.2 billion each year. Published research in Thrombosis & Haemostasis shows VTEs cost the U.S. VTE is a collective term encompassing deep vein thrombosis (DVT), a blood clot in a deep vein usually the leg, and pulmonary embolism (PE), when a clot travels to the lung. ![]() VTE affects more than 900,000 Americans each year one-third of these episodes will be fatal. The economic analysis, presented today at the Hospital Medicine 2016 congress, compared the cost savings associated with treatment with XARELTO®, a non-vitamin K antagonist oral anticoagulant (NOAC), to warfarin in the hospital setting. ![]() hospitals using XARELTO® (rivaroxaban) instead of warfarin to treat patients diagnosed with a venous thromboembolism (VTE) may save, on average, almost $2,000 per patient and shorten a patient’s hospital stay by approximately 1.5 days. SAN DIEGO, CA (March 7, 2016) – A new, real-world study found U.S.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |